Royal Bank of Canada Buys 759,984 Shares of ADMA Biologics Inc $ADMA

Key Points

• Royal Bank of Canada increased its ADMA Biologics stake by 448.8%, purchasing 759,984 shares to own 929,326 shares valued at approximately $8.37 million, or 0.40% of the company.
• ADMA reported quarterly EPS of $0.16, in line with estimates, while revenue of $124.39 million slightly missed expectations; revenue rose 2% year over year. Institutional investors collectively own 75.68% of the stock.
• Analyst sentiment is mixed, with an average “Hold” rating and $18.67 price target, while several law firms are publicizing a pending securities lawsuit involving alleged financial and revenue-reporting misrepresentations.

Royal Bank of Canada raised its position in shares of ADMA Biologics Inc (NASDAQ:ADMA - Free Report) by 448.8% in the first quarter, according to its most recent filing with the SEC. The firm owned 929,326 shares of the biotechnology company's stock after purchasing an additional 759,984 shares during the quarter. Royal Bank of Canada owned approximately 0.40% of ADMA Biologics worth $8,373,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in ADMA. Rubric Capital Management LP bought a new stake in shares of ADMA Biologics in the 1st quarter valued at $16,303,000. Ashford Capital Management Inc. bought a new position in ADMA Biologics during the first quarter worth $3,257,000. Quantinno Capital Management LP lifted its holdings in ADMA Biologics by 31.2% in the first quarter. Quantinno Capital Management LP now owns 42,541 shares of the biotechnology company's stock valued at $383,000 after buying an additional 10,108 shares during the period. Rice Hall James & Associates LLC boosted its position in ADMA Biologics by 3.0% during the first quarter. Rice Hall James & Associates LLC now owns 300,744 shares of the biotechnology company's stock valued at $2,710,000 after acquiring an additional 8,809 shares during the last quarter. Finally, Keebeck Wealth Management grew its holdings in ADMA Biologics by 9.7% during the 1st quarter. Keebeck Wealth Management now owns 35,459 shares of the biotechnology company's stock worth $319,000 after acquiring an additional 3,136 shares during the period. Institutional investors own 75.68% of the company's stock.

ADMA Biologics Stock Down 1.5%

ADMA stock opened at $9.75 on Tuesday. The firm has a market capitalization of $2.26 billion, a PE ratio of 13.93 and a beta of 0.74. The company has a quick ratio of 3.81, a current ratio of 6.97 and a debt-to-equity ratio of 0.49. ADMA Biologics Inc has a twelve month low of $7.21 and a twelve month high of $20.46. The stock's 50 day moving average is $8.67 and its 200-day moving average is $11.21.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last announced its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $0.16 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.16. The business had revenue of $124.39 million during the quarter, compared to the consensus estimate of $125.34 million. ADMA Biologics had a return on equity of 40.17% and a net margin of 32.98%.ADMA Biologics's revenue was up 2.0% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.14 earnings per share. Sell-side analysts expect that ADMA Biologics Inc will post 0.76 EPS for the current fiscal year.

Key Headlines Impacting ADMA Biologics

Here are the key news stories impacting ADMA Biologics this week:

• Neutral Sentiment: The August 10, 2026 deadline allows investors who purchased ADMA securities between August 9, 2024, and March 25, 2026, to apply to become lead plaintiff. The notices state that eligible investors may pursue compensation through a contingency-fee arrangement, but the announcements do not establish that ADMA violated securities laws. Rosen Law Firm deadline notice
• Negative Sentiment: Hagens Berman said the lawsuit concerns alleged misrepresentations about ADMA’s financial condition, revenue recognition, inventory distribution and business practices. The allegations could increase legal costs, create potential liability and undermine investor confidence if they proceed. Hagens Berman class-action notice
• Negative Sentiment: Rosen, Faruqi & Faruqi, DJS Law Group and Schall, Brown & Schwartz separately promoted the pending securities action and encouraged affected shareholders to contact them. The unusually large number of substantially similar notices may amplify short-term headline pressure on ADMA, although they largely repeat the same underlying litigation information. Faruqi & Faruqi class-action deadline DJS Law Group lawsuit notice

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on ADMA shares. Canaccord Genuity Group lowered their price objective on ADMA Biologics from $21.00 to $18.00 and set a "buy" rating for the company in a research report on Thursday, May 7th. Raymond James Financial assumed coverage on ADMA Biologics in a research note on Wednesday, June 10th. They set an "outperform" rating and a $21.00 target price for the company. Weiss Ratings reiterated a "hold (c)" rating on shares of ADMA Biologics in a report on Thursday, June 18th. Mizuho dropped their price target on ADMA Biologics from $20.00 to $17.00 and set an "outperform" rating on the stock in a research note on Wednesday, July 15th. Finally, Zacks Research cut ADMA Biologics from a "hold" rating to a "strong sell" rating in a report on Tuesday, August 4th. Three research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, ADMA Biologics currently has an average rating of "Hold" and an average target price of $18.67.

ADMA Biologics Profile

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company's marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source